MicroRNA controlled adenovirus mediates anti-cancer efficacy without affecting endogenous microRNA activity.
MicroRNAs are small non-coding RNA molecules that regulate mRNA translation and stability by binding to complementary sequences usually within the 3' un-translated region (UTR). We have previously shown that the hepatic toxicity caused by wild-type Adenovirus 5 (Ad5WT) in mice can be prevented by incorporating 4 binding sites for the liver-specific microRNA, mir122, into the 3' UTR of E1A mRNA. This virus, termed Ad5mir122, is a promising virotherapy candidate and causes no obvious liver pathology. Herein we show that Ad5mir122 maintains wild-type lytic activity in cancer cells not expressing mir122 and assess any effects of possible mir122 depletion in host cells. Repeat administration of 2×10(10) viral particles of Admir122 to HepG2 tumour bearing mice showed significant anti-cancer efficacy. RT-QPCR showed that E1A mRNA was down-regulated 29-fold in liver when compared to Ad5WT. Western blot for E1A confirmed that all protein variants were knocked down. RT-QPCR for mature mir122 in infected livers showed that quantity of mir122 remained unaffected. Genome wide mRNA microarray profiling of infected livers showed that although the transcript level of >3900 different mRNAs changed more than 2-fold following Ad5WT infection, less than 600 were changed by Ad5mir122. These were then filtered to select mRNAs that were only altered by Ad5mir122 and the remaining 21 mRNAs were compared to predicted mir122 targets. No mir122 target mRNAs were affected by Ad5 mir122. These results demonstrate that the exploitation of microRNA regulation to control virus replication does not necessarily affect the level of the microRNA or the endogenous mRNA targets.
Medicinal Virology Research Group, Department of Clinical Pharmacology, University of Oxford, Oxford, United Kingdom.
Ryan
R
Cawood
Suet-Ling
SL
Wong
Ying
Y
Di
Dilair F
DF
Baban
Leonard W
LW
Seymour
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D056945:Hep G2 Cells; D006801:Humans; D008099:Liver / Q000737:chemistry; D051379:Mice; D035683:MicroRNAs / Q000032:analysis / Q000627:therapeutic use*; D009374:Neoplasms, Experimental / Q000628:therapy*; D014183:Transplantation, Heterologous; D016896:Treatment Outcome; D014771:Virion
C548375:MIRN22 microRNA, human; D035683:MicroRNAs
J Virol. 1996 Nov;70(11):7498-509
8892868
Mol Ther. 2009 Mar;17(3):409-16
19107117
Mol Ther. 2008 Oct;16(10):1719-1726
28189004
J Virol. 2010 Feb;84(3):1550-62
19906911
Cancer Res. 2005 Nov 1;65(21):9982-9990
16267023
Nat Biotechnol. 2007 Dec;25(12):1457-67
18026085
Prostate. 2009 Jan 1;69(1):82-91
18973133
Nat Biotechnol. 2009 Jun;27(6):572-6
19483680
J Gen Virol. 1978 Jul;40(1):45-61
211182
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
11752295
Cancer Chemother Pharmacol. 1989;24(3):148-54
2544306
RNA. 2008 Feb;14(2):336-46
18073344
Cell Host Microbe. 2008 Sep 11;4(3):239-48
18779050
PLoS Pathog. 2009 May;5(5):e1000440
19461878
Cancer Cell. 2003 Oct;4(4):263-75
14585354
Nat Med. 2006 May;12(5):585-91
16633348
Cancer Gene Ther. 2004 Dec;11(12):819-29
15359291
Eur Urol. 2010 May;57(5):919
20945549
RNA Biol. 2004 Jul;1(2):106-13
17179747
Science. 2007 Sep 21;317(5845):1764-7
17656684
Nucleic Acids Res. 2001 May 1;29(9):e45
11328886
Hum Gene Ther. 2008 Sep;19(9):873-86
18710328
Biochem Biophys Res Commun. 2010 Jun 4;396(3):596-601
20412785
J Virol. 2010 Aug;84(15):7713-25
20504925
Cancer Gene Ther. 2006 Jul;13(7):696-705
16498429
J Virol. 2008 Nov;82(22):11009-15
18799589
Nat Med. 2008 Nov;14(11):1278-83
18953352
Mol Ther. 2008 Aug;16(8):1437-43
18560417
Cell Metab. 2006 Feb;3(2):87-98
16459310
Nat Methods. 2009 Jan;6(1):63-6
19043411
Oncogene. 2009 Oct 8;28(40):3526-36
19617899
Nature. 2006 May 25;441(7092):537-41
16724069
Virology. 2004 Oct 10;328(1):52-61
15380358